Related by context. All words. (Click for frequent words.) 76 NIHSS 70 EDSS score 68 YMRS 68 NIH CPSI 68 MMSE score 67 ADAS cog 67 Index CDAI 67 EDSS scores 67 Expanded Disability Status 66 Unified Parkinson Disease 66 WOMAC pain 66 Crohn Disease Activity 66 NIHSS score 66 HDRS 65 Scale EDSS 65 MADRS score 65 Montgomery Asberg Depression 65 APACHE II 64 IBDQ 64 preoperative PSA 64 MADRS 64 biochemical recurrence 64 Rating Scale MADRS 64 SGRQ 64 mTSS 64 DAS# remission 64 Disease Activity 63 Y BOCS 63 UPDRS 63 ALT elevation 63 Brief Psychiatric 63 Rating Scale UPDRS 63 HAQ DI 63 PANSS 63 Pain Intensity 63 Health Assessment Questionnaire 63 Hb A1C 63 subscore 63 Montgomery Åsberg Depression 63 CDAI score 63 PSADT 63 p = #.# [003] 62 % Confidence Interval 62 methotrexate monotherapy 62 posttreatment 62 biopsy Gleason 62 adjunctive placebo 62 NYHA functional class 62 Scale EDSS score 62 HAM D# 62 PSA nadir 62 HOMA IR 62 % CI #.#-#.# [007] 62 antibody titer 62 anemia hemoglobin 62 Status Scale EDSS 62 Ishak fibrosis score 62 liver histology 62 adjunctive ABILIFY 61 EDSS 61 virological response 61 WOMAC 61 HADS 61 CR nPR 61 DAS# [002] 61 HbA 1c levels 61 Global Impression CGI 61 plasma cortisol 61 univariate analyzes 61 affective psychosis 61 confidence intervals CIs 61 Alzheimer Disease Assessment 61 Visual Analogue Scale VAS 61 MMSE scores 61 pCR 61 BMI z 61 Kaplan Meier estimates 61 glycated hemoglobin levels 61 clinically meaningful improvement 61 baseline HbA1c 61 depressive symptom 61 nonobese 61 subscale scores 61 International Prostate Symptom 61 ADCS CGIC 61 PANSS total 61 SCr 61 annualized relapse 60 EQ 5D 60 subscores 60 multivariate analyzes 60 virologic response 60 univariate 60 Rating Scale BPRS 60 recurrent venous thromboembolism 60 neurocognitive function 60 serologically active patients 60 Postoperatively 60 IRLS 60 Operative mortality 60 nondiabetic patients 60 logistic regression analyzes 60 serum HBV DNA 60 pT3 60 DAS# scores 60 lymphocyte count 60 p = .# [002] 60 Clinician Administered PTSD 60 Kaplan Meier method 60 IRLS score 60 HBeAg seroconversion 60 univariate analysis 60 elevated LDH 60 HbA 1c 60 CI #.#-#.# [001] 60 mL/min/#.# m 2 60 PASI scores 60 serum testosterone 60 CIN3 60 hemoglobin A1c levels 60 Glasgow Coma Scale 60 CORE OM 59 neurodevelopmental impairment 59 PANSS scores 59 perioperative complications 59 nonoperative treatment 59 DAS# CRP 59 HbA1C levels 59 gadolinium enhancing lesions 59 hip BMD 59 nonfatal MI 59 covariate 59 intact parathyroid hormone 59 #.#ng/ml 59 Visual Analog 59 extrapyramidal side 59 log# reduction 59 conditional logistic regression 59 haematologic 59 treat NNT 59 PSQI 59 atheroma volume 59 sensory neuropathy 59 P = .# 59 albumin excretion rate 59 symptom severity 59 pulmonary dysfunction 59 arterial thickening 59 % CI #.#-#.# [003] 59 hip resurfacing arthroplasty 59 ADAS Cog 59 biochemical relapse 59 FDA defined valvulopathy 59 SUVmax 59 HRQL 59 Preoperatively 59 serum cortisol 59 attain statistical significance 59 poststroke 59 periprocedural 59 femoral neck BMD 59 serum urate 59 #q# deletion syndrome 59 extrapyramidal symptoms 59 nonparametric 59 multivariable analysis 59 ETDRS 59 Timed Walk 59 CCyR 59 UPDRS motor 59 subscales 59 Negative Syndrome 59 Visual acuity 59 interrater reliability 59 Global Impression 59 cranial irradiation 59 Abnormal Involuntary Movement 59 macroalbuminuria 59 neutrophil counts 59 MetS 59 CDAI 59 perioperative mortality 59 Kaplan Meier curves 59 virologic failure 59 HRQOL 59 lumbar spine BMD 59 LV ejection fraction 59 endometrial thickness 59 logistic regression analysis 59 HAM D# scores 59 symptom exacerbation 59 specific antigen PSA 59 Kaplan Meier analysis 59 serum parathyroid hormone 59 placebo p = 58 Lumbar spine 58 glomerular filtration 58 QIDS SR 58 allele frequencies 58 logistic regression model 58 Depression Inventory 58 Main Outcome Measure 58 logistic regression 58 leukocyte count 58 ejection fractions 58 alanine aminotransferase ALT 58 ECOG PS 58 certolizumab 58 estimated glomerular filtration 58 ACR# response 58 SVR# 58 radiographic progression 58 CD4 + cell 58 ACR Pedi 58 histological subtype 58 beta blocker therapy 58 REYATAZ r arm 58 binary restenosis 58 psychiatric comorbidity 58 morphometric vertebral fractures 58 multivariable adjusted 58 T2DM 58 diabetes mellitus DM 58 NNT = 58 Score DAS# 58 logistic regression models 58 Psoriasis Area 58 ADCS ADL 58 p = NS 58 psychosocial functioning 58 reinfarction 58 oxycodone CR 58 Mania Rating Scale 58 estimated GFR 58 Sustained virologic response 58 Primary endpoints 58 creatinine ratio 58 Stent thrombosis 58 Baseline characteristics 58 prognostic variables 58 serum aminotransferase levels 58 Scale cognitive subscale 58 mg kg dose 58 μmol L 58 WOMAC TM 58 Postoperative 58 dichotomized 58 HAMD 58 graft dysfunction 58 tertiles 58 Pred Forte 58 CsA 58 5-FU/LV 58 Subgroup analysis 58 elevated ALT 58 platelet reactivity 58 posttransplant 58 MACCE 58 Ejection Fraction 58 Dyspnea 58 CI -#.# 58 lactate dehydrogenase LDH 58 Secondary endpoints included 58 HBeAg negative patients 58 polyp recurrence 58 nonsignificant 58 postoperative mortality 58 Kruskal Wallis test 58 ALSFRS R 58 pairwise comparisons 58 postprocedure 58 SSRI SNRI 58 chi squared 58 postinjury 58 Kaplan Meier survival 58 postoperative complication 58 neutropaenia 58 histologic subtype 58 ‰ ¥ 58 regression coefficient 58 androgen suppression 58 akinesia 58 bivariate analyzes 58 plasma leptin 58 TEAEs 58 Scale PANSS 57 fasting triglyceride levels 57 HER2 expression 57 unpaired t 57 transaminase elevations 57 Viral load 57 hematologic toxicity 57 intima media thickness 57 Insulin sensitivity 57 ANCOVA 57 aspartate aminotransferase AST 57 secondary efficacy endpoint 57 FACIT Fatigue 57 CPAP adherence 57 System IPSS 57 % CI #.#-#.# [004] 57 p = #.# [002] 57 p = .# [001] 57 virological failure 57 State Examination MMSE 57 laboratory abnormalities 57 Fibromyalgia Impact Questionnaire 57 albumin excretion 57 Charlson comorbidity index 57 Index CDAI score 57 sd = 57 â ‰ ¥ 57 SELENA SLEDAI score 57 radical prostatectomy RP 57 leukocyte counts 57 -#.# ± [002] 57 elevated transaminases 57 mg BID dose 57 postop 57 moderate renal impairment 57 serum PSA 57 recurrent VTE 57 % CI #.#-#.# [006] 57 serum urate levels 57 nondepressed 57 HRQoL 57 Kaplan Meier 57 serum creatinine levels 57 euthyroid 57 postintervention 57 mild renal insufficiency 57 oocytes retrieved 57 TNSS 57 LVEF 57 T2 lesion volume 57 receiving VICTRELIS 57 P ≤ 57 arterial thromboembolic events 57 definite stent thrombosis 57 ng dL 57 nonvertebral fracture 57 MDRD 57 baseline LDH 57 salivary cortisol 57 concomitant medications 57 ALT elevations 57 ipsilateral stroke 57 lopinavir r arm 57 NPH insulin 57 ml kg 57 symptomatic VTE 57 χ 57 symptomatic intracranial hemorrhage 57 x ULN 57 tipranavir ritonavir 57 preoperative chemotherapy 57 placebo fluoxetine 57 undetectable HBV DNA 57 receiving ISENTRESS 57 lactate dehydrogenase 57 KOOS 57 POAG 57 aminotransferase levels 57 adenoma recurrence 57 BPRS PSS 57 #OHD 57 androgen deprivation 57 splenectomized patients 57 Flu Cy 57 Follicular Lymphoma 57 IDDM 57 artery stenosis 57 #Gy 57 ELBW infants 57 odds ratios ORs 57 CrCl 57 Depression Rating Scale 57 Visual Analog Scale 57 F FDG PET 57 NSTEMI 57 HAM D 57 Physical Component 57 Severity Index PASI 57 LV dysfunction 57 QoL 57 tumor histology 57 erection hardness 57 mcg BID 56 Decitabine 56 plus methotrexate 56 carotid stenosis 56 bivariate 56 CNS LS 56 tipranavir r 56 SELENA SLEDAI 56 nadroparin 56 Main Outcome Measures 56 Bonferroni correction 56 MMSE 56 cytogenetic response 56 myocardial reperfusion 56 achieved ACR# 56 depressive symptomatology 56 carotid IMT 56 preoperatively 56 p ≤ 56 X ULN 56 ADHD RS 56 QRS duration 56 peri procedural 56 β blocker 56 lymphocyte counts 56 hemoglobin Hb 56 Oswestry Disability Index 56 sUA 56 glomerular filtration rate 56 serum ALT 56 APOE genotype 56 placebo p 56 umol L 56 NNRTI resistance 56 EBRT 56 esophageal carcinoma 56 cerebrovascular events 56 intraobserver 56 demonstrated clinically meaningful 56 spirometric 56 nonischemic 56 multivariate Cox 56 Univariate analysis 56 Secondary endpoints include 56 #.#/#.# mm Hg [003] 56 MoxDuo TM IR 56 paricalcitol 56 nonoperative 56 SLNB 56 nerve conduction velocity 56 CHD mortality 56 ß = 56 Multivariate analysis 56 colorectal adenoma 56 Serum creatinine 56 cells mcL 56 genotypic resistance 56 SSc 56 postoperative AF 56 β = 56 obstructive CAD 56 sociodemographic factors 56 gadolinium enhanced 56 β blockers 56 MCyR 56 lowest tertile 56 hemoglobin A1c HbA1c 56 clodronate 56 Logistic regression analysis 56 Fasting plasma glucose 56 systolic dysfunction 56 neurologic impairment 56 pmol L 56 death reinfarction 56 AUA Symptom Score 56 Rating Scale 56 adefovir treated 56 timepoint 56 aPTT 56 APTIVUS r 56 Apgar scores 56 peak VO2 56 CHADS2 56 QTcF 56 histologically proven 56 octreotide LAR 56 timepoints 56 fasting plasma glucose FPG 56 advanced adenoma 56 Adjuvant chemotherapy 56 aminotransferases 56 Response Evaluation Criteria 56 alteplase 56 virologic responses 56 CK MB 56 unfractionated heparin UFH 56 periprocedural MI 56 Comorbidity 56 triiodothyronine 56 IPSS 56 ECLS 56 Secondary endpoints 56 systolic BP 56 perioperatively 56 sustained virological response 56 Target Lesion Revascularization TLR 56 Thrombolysis 56 creatinine clearance 56 clinicopathological features 56 = #.#-#.# 56 angiographically 56 intravitreal injections 56 affective psychoses 56 asymptomatic carotid stenosis 56 NYHA class 56 4mg/kg 56 alanine aminotransferase 56 intraventricular hemorrhage 56 Score DAS 56 FDG uptake 56 nonsignificant difference 56 thrombocytopenic 56 HbA1c levels 56 chlorambucil 56 ASIA Impairment 56 severe exacerbations 56 venlafaxine XR 55 HSCT 55 inhospital mortality 55 ischemic lesions 55 rimonabant #mg 55 nonischemic cardiomyopathy 55 baseline FEV 55 chemoradiotherapy 55 autonomic dysfunction 55 infarcts 55 HIV HCV coinfected 55 postoperative morbidity 55 troponin T 55 International Prognostic Scoring 55 CRp 55 Distress Scale 55 syndromal 55 Severity MSCS score 55 PCa 55 pelvic lymphadenectomy 55 biventricular repair 55 apnea hypopnea index 55 aspartate aminotransferase 55 elevated IOP 55 tertile 55 EBMT criteria 55 acute cholecystitis 55 coinfected 55 serum testosterone levels 55 STN stimulation 55 inhibin 55 malabsorptive 55 bronchopulmonary dysplasia 55 SGPT 55 vasopressor 55 complete cytogenetic response 55 prespecified 55 tolvaptan 55 virologic suppression 55 psychosocial variables 55 statistically significant p = 55 serum folate concentrations 55 WOMAC scores 55 ROC curve 55 8mg/kg 55 meta analytic 55 hours postdose 55 hypoglycemic events 55 highly emetogenic 55 ARB telmisartan 55 CD4 CD8 55 dose atorvastatin 55 % CI #.#-#.# [008] 55 T2 lesions 55 mmHg diastolic 55 corticosteroid dose 55 serum HCV RNA 55 locomotor activity 55 ± SEM 55 -5 -6 55 Poisson regression 55 multivariate logistic regression 55 overt hypothyroidism 55 Knodell necroinflammatory score 55 OGTT 55 Non inferiority 55 postoperatively 55 atorvastatin #mg 55 detrusor overactivity 55 overactive bladder symptoms 55 plasma HCV RNA 55 recurrent glioblastoma multiforme 55 CIMZIA TM certolizumab pegol 55 Hamilton Rating Scale 55 antiretroviral naïve 55 left ventricular systolic 55 lymphopenia 55 non menstrual pelvic 55 fasting insulin 55 dyssynchrony 55 sustained virologic response 55 DLQI 55 clinically meaningful improvements 55 nonfatal myocardial infarction 55 BYSTOLIC 55 squamous histology 55 untreated psychosis 55 IOP lowering 55 CR CRu 55 Logistic regression 55 decompensated cirrhosis 55 hepatic fibrosis 55 R0 resection 55 undetectable HCV RNA 55 paraprotein 55 glycosylated hemoglobin HbA1c 55 abacavir lamivudine 55 prospectively defined 55 HBeAg 55 interobserver reliability 55 serum calcium levels 55 serum bilirubin 55 kidney allograft 55 Thrombocytopenia 55 lamivudine monotherapy 55 ANOVA 55 aortic insufficiency 55 salmeterol fluticasone propionate 55 serum concentrations 55 PREZISTA r arm 55 intravaginal ejaculatory latency 55 Free Survival PFS 55 adrenal function 55 relapsed MM 55 nontreated 55 extubation 55 hypopneas 55 progression TTP 55 baseline A1C 55 subclinical hypothyroidism 55 everolimus eluting stents 55 leucopenia 55 euthymic patients 55 XIENCE V PROMUS Stent 55 serum estradiol 55 CP CPPS 55 hepatitis C genotype 55 serum folate 55 Negative Symptoms 55 comorbidity 55 alanine transaminase 55 serum IGF 55 intraclass correlation coefficient 55 HPA axis suppression 55 glycated hemoglobin HbA1c 55 saline placebo 55 preterm neonates 55 CVD mortality 55 atrioventricular valve 55 IFN beta 55 ≥ 55 confidence interval #.#-#.# 55 PaO 2 55 prespecified secondary 55 Neuropsychiatric Inventory 55 doxorubicin docetaxel 55 FOLPI 55 transaminase levels 55 pain subscale 55 rho = 55 eszopiclone 55 IFN α 55 methacholine challenge 55 LVNC 55 receiving golimumab 55 mg XP# 55 hepatectomy 55 pg ml 55 elevated bilirubin 55 severe neutropenia 55 hypoglycemic episodes 55 achieved statistical significance 55 CIMZIA TM 55 Doxil ® 55 prolactin levels 55 triglyceride concentration 55 postoperative pulmonary 55 UPDRS Part III 55 Skin sterol 55 dosing cohort 55 thyroglobulin 55 nonmetastatic prostate cancer 55 preintervention 55 urinary albumin excretion 55 cognitive affective 55 baseline CD4 55 Mantel Haenszel 55 oncologic outcomes 55 serum sodium 55 thyrotropin levels 55 complete cytogenetic 55 CYP#D# genotype 55 leukocytosis 55 fatty infiltration 55 Respiratory Symptoms 55 antihypertensive therapy 55 prospectively stratified 55 Key secondary endpoints 55 nonfasting triglyceride levels 55 noncardiovascular mortality 55 Solid Tumors criteria 55 CC genotype 55 CFQ R 54 F FDG uptake 54 multivariable analyzes 54 advanced adenomas 54 multivariate adjustment 54 uncorrected visual acuity 54 neutrophil count 54 WAIS III 54 angiographic restenosis 54 pulmonary exacerbations 54 tolterodine ER 54 mcg albinterferon alfa 2b 54 variance ANOVA 54 PegIFN RBV 54 lymphocytosis 54 hippocampal volume 54 remission CR 54 myocardial viability 54 locoregional disease 54 NMIBC 54 urine albumin 54 regression analyzes 54 subsyndromal 54 psychiatric comorbidities 54 heterozygotes 54 atrioventricular block 54 serum phosphate 54 docetaxel pretreated 54 seminal vesicle invasion 54 leukopenia 54 #mg dose [002] 54 mcg QD 54 calculated creatinine clearance 54 ADHD Rating Scale 54 serum homocysteine 54 mean ± SEM 54 coronary stenosis 54 postdischarge 54 hematopoietic cancers 54 histologically confirmed 54 nonobese patients 54 Pain Rating Scale 54 analgesic medications 54 nmol L. 54 serum phosphorous 54 Prehypertension 54 nonvertebral fractures 54 multivariable Cox 54 undergoing CABG 54 eplerenone 54 experienced virologic failure 54 Visual Analogue Scale 54 HBV DNA 54 6MWT 54 RAPAFLO R 54 depressive symptoms 54 plasma viremia 54 metabolic parameters 54 PREZISTA ritonavir 54 postoperative delirium 54 nonmalignant 54 Cystatin C 54 overt nephropathy 54 thrombolytic therapy 54 TEVAR 54 IV bisphosphonates 54 lymphadenectomy 54 chloride secretion 54 T1DM 54 point Likert scale 54 AGILECT R 54 vertebral fracture 54 HbA1C 54 Prostate specific antigen 54 RLAI 54 CIN2 + 54 femoral shaft fracture 54 inflammatory biomarkers 54 Symptom severity 54 LVSD 54 Natalizumab 54 bioavailable testosterone 54 p = #.# [004] 54 SSRI citalopram 54 osteopenic 54 euthymic 54 serum phosphate levels 54 Kaplan Meier curve 54 systolic function 54 somatic symptom 54 methotrexate therapy 54 symptomatology 54 serum magnesium 54 plasma folate 54 hippocampal volumes 54 PAOD 54 afterload 54 serum BDNF 54 Cmax 54 quetiapine 54 anagrelide 54 prostate cancer CaP 54 corrected QT interval 54 anemia neutropenia 54 comorbid disorders 54 -#.# log# 54 decompensation Child Pugh 54 RECIST Response Evaluation Criteria 54 arterial oxygen saturation 54 FDG PET imaging 54 hematologic parameters 54 composite endpoint 54 prolactin elevation 54 p = 54 interindividual variability 54 evaluable subjects 54 postoperative infections 54 glycated hemoglobin 54 binary logistic regression 54 sociodemographic characteristics 54 preserved ejection fraction 54 creatinine levels 54 Viread Emtriva Sustiva 54 ug kg 54 Aspergillus infections 54 neostigmine 54 gait disturbances 54 serum uric acid 54 AVODART 54 neurologic dysfunction 54 hypogonadal men 54 posttest 54 refractory ischemia 54 hepatorenal syndrome 54 reperfusion therapy 54 anthropometric measures 54 aldosterone antagonist 54 angiotensin converting enzyme inhibitors 54 subclinical hyperthyroidism 54 mg TID 54 decrements 54 EORTC QLQ C# 54 vitreous haze 54 rebleeding 54 dichotomous variables 54 nulliparous women 54 confidence interval CI 54 plasma homocysteine 54 HLA DR4 54 GnRH agonist 54 premorbid 54 noncardiac 54 NYHA 54 TPV r 54 non affective psychosis 54 autoimmune thyroid 54 IELT 54 operable breast cancer 54 oral anticoagulation 54 dysthymia 54 nodular partial response 54 #mg/day [002] 54 Inventory BPI 54 dapagliflozin plus 54 BPH Symptom Score 54 Capacity FVC 54 mmol l 54 steatohepatitis 54 function subscale 54 serum CRP 54 TRAS 54 affective disorders 54 asymptomatic PAD 54 HbA 1C 54 FOLFOX4 54 endoleak 54 somatostatin analog 54 chemoradiation therapy 54 Partial Response 54 undetectable viral 54 ropivacaine 54 urinary albumin 54 Erectile function 54 intracranial hypertension 54 preinjury 54 Histologic 54 caspofungin 54 hypoxemia 54 Heavy menstrual bleeding 54 p = ns 54 polytherapy 54 reflux symptoms 54 coinfected patients 54 serum calcium 54 mg ustekinumab 54 subanalysis 54 dose Iluvien 54 Ischemic 54 dyspnoea 54 inotropic 54 sirolimus eluting stents 54 LS BMD 54 intraventricular 54 neoadjuvant chemotherapy 54 Febrile neutropenia 54 tapentadol ER 54 joint contracture 54 BPRS 54 apolipoprotein B 54 hypogonadal 54 solifenacin 54 hypofractionated radiation 54 Ocular Surface Disease 54 ASCUS 54 foveal thickness 54 pericardial effusion 54 liver enzymes ALT 54 Hypotension 53 serum lipid levels 53 flow mediated dilation 53 perfusion abnormalities 53 STRIDE PD 53 urate lowering therapy 53 neovascular 53 bivariate analysis 53 postoperative chemotherapy 53 + PH# 53 GH deficiency 53 mammographic density 53 RLS symptoms 53 CNV lesion 53 adiponectin concentrations 53 VFQ 53 symptomatic intracerebral hemorrhage 53 corneal astigmatism 53 liver metastasis 53 bortezomib refractory 53 mitoxantrone chemotherapy 53 Kellgren Lawrence 53 serum potassium 53 androgen depletion 53 interquartile range 53 nighttime awakenings 53 multivariable logistic regression 53 antidiabetic medication 53 seropositive patients 53 AST ALT 53 blood Phe levels 53 primary percutaneous coronary 53 clomipramine 53 -#.# mg dL [002] 53 nonresponders 53 inotropic agents 53 serum prostate 53 Global Impression Severity 53 DSM IV diagnosis 53 surrogate endpoint 53 proliferative diabetic retinopathy 53 intracerebral haemorrhage 53 median CD4 53 pretest probability 53 perioperative morbidity 53 insulin detemir 53 de novo AML 53 fractional anisotropy 53 rhinoconjunctivitis 53 antihypertensive medications 53 Depression Scale 53 ALND 53 airflow obstruction 53 mg/m2 dose 53 BPH symptom 53 subthreshold depression 53 ≤ 53 malignant neoplasm 53 irbesartan 53 varicocele 53 Score TOS 53 CHADS 53 decompensated heart failure 53 Sleep disturbances 53 urinary symptoms 53 Rosenberg Self Esteem 53 microsatellite instability 53 hypoglycaemic episodes 53 baseline PASI 53 antithrombotic therapy 53 adalimumab 53 TURBT 53 Subgroup analyzes 53 Acute Physiology 53 metastatic lung cancer 53 mRCC 53 adverse perinatal